New drug approved by TGA to treat Lupus
The Australian Therapeutic Goods Administration (TGA) has approved Saphnelo for use in Australia. Saphnelo is expected to be available for Lupus patients in the next few months. TGA has made the following public statement:
“Saphnelo (anifrolumab) was approved for the following therapeutic use:
Saphnelo (anifrolumab) is indicated as add on treatment of adult patients with moderate to severe, active systemic lupus erythematosus (SLE), despite standard therapy. The safety and efficacy of Saphnelo have not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus.”
For more information on Saphnelo, click here for more information on Consumer Medical Information (CMI) on Saphnelo.
